Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024

Aligos Therapeutics, Inc.

2024-Q1 EPS reported -$0.22 revenue$694,000

Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.
Cash and investments $112.7M, down from $135.7M at Dec 2023; runway through end of 2025.
Phase 2a HERALD study (ALG-055009 for MASH) started dosing April 2024; topline data expected Q4 2024.
Received additional $1.3M NIH grant for pan-coronavirus protease inhibitor ALG-097558; Phase 2 enabling activities underway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported first quarter 2024 results: net income Net losses for the three months ended March 31, 2024 were $34.9 million, EPS basic and diluted net loss per common share of $(0.22).

Period: first quarter 2024
Net income: Net losses for the three months ended March 31, 2024 were $34.9 million
EPS: basic and diluted net loss per common share of $(0.22)
Result: reported results

Exact text from the filing

Net losses for the three months ended March 31, 2024 were $34.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $23.0 million or basic and diluted net loss per common share of $(0.53) for the three months ended March 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.